近日，专注于罕见病治疗领域的生物科技公司锐康迪（Recodi Therapeutics）宣布正式进入清算程序，引发行业广泛关注。据公司公告，由于核心研发管线在关键临床试验中未能达到预期疗效终点，叠加融资环境持续收紧，公司现金流枯竭，董事会经审慎评估后决定启动自愿清算程序。锐康迪自成立以来，致力于开发针对遗传性代谢疾病和神经退行性罕见病的创新疗法，曾获得多轮融资，并与多家科研机构建立合作关系。然而，新药研发周期长、投入大、成功率低的特点，使其在缺乏重磅产品上市支撑的情况下难以维持长期运营。此次清算不仅意味着公司业务终止，也反映出当前全球生物技术初创企业在资本寒冬下面临的巨大生存压力。业内专家指出，尽管锐康迪的退出令人惋惜，但其积累的临床数据和科研成果或可为后续研究提供宝贵参考。同时，该事件再次凸显了罕见病药物研发领域对政策支持、风险投资及多元化资金渠道的迫切需求。
Recently, Recodi Therapeutics, a biotech company focused on rare disease treatments, announced it has officially entered liquidation proceedings, drawing significant attention from the industry. According to the company’s statement, its lead drug candidates failed to meet primary endpoints in pivotal clinical trials, and combined with a persistently tight financing environment, this led to severe cash flow shortages. After careful evaluation, the board decided to initiate a voluntary liquidation process. Since its inception, Recodi had been dedicated to developing innovative therapies for inherited metabolic disorders and neurodegenerative rare diseases, securing multiple rounds of funding and establishing collaborations with various research institutions. However, the long development timelines, high costs, and low success rates inherent in drug discovery made sustained operations untenable without a market-approved breakthrough product. The liquidation not only marks the end of the company’s operations but also highlights the intense survival pressures facing global biotech startups amid a capital winter. Industry experts noted that while Recodi’s exit is regrettable, the clinical data and scientific insights it generated could still offer valuable references for future research. The event further underscores the urgent need for policy support, risk-tolerant investment, and diversified funding mechanisms in the rare disease drug development landscape.
原创文章，作者：admin，如若转载，请注明出处：https://ktez.cn/11639.html